Two sides to the eosinophil story
*According to the American Thoracic Society (ATS) and European Respiratory Society (ERS), severe asthma is a type of asthma that requires treatment with high-dose inhaled corticosteroids (ICS), plus a second controller and/or systemic corticosteroid to prevent it from becoming uncontrolled, or asthma that remains uncontrolled despite this therapy.4
†Exacerbations of asthma were defined as the worsening of asthma that required use of oral/systemic corticosteroids and/or hospitalization and/or emergency department (ED) visits; for patients on maintenance oral/systemic corticosteroids, exacerbations were defined as requiring at least double the existing maintenance dose for at least 3 days.
- Weller PF, Spencer LA. Functions of tissue-resident eosinophils. Nat Rev Immunol. 2017;17:746-757.
- Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med. 2005;172(2):149-160.
- Malinovschi A, Fonseca JA, Jacinto T, Alving K, Janson C. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol. 2013;132(4):821-827 e5.
- Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343-373.
- Wagener AH, de Nijs SB, Lutter R, et al. External validation of blood eosinophils, FeNO and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70(2):115-120.